TharImmune Shares Soar 57% After FDA Greenlights TH104 Pathway
By ATTN Desk · Editorial oversight: Sean Han
Biotechnology by Sangharsh Lohakare
THARIMMUNE INC (THAR: NAS) Advances Clinical Programs amid Stock Rally
Introduction
THARIMMUNE INC (ticker: THAR) is a clinical-stage biotechnology company focused on immunology, inflammation, and oncology. Its lead candidate, TH104, is being developed via a 505(b)(2) pathway for the prophylaxis of respiratory and nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids. The portfolio includes TH104 for chronic pruritus associated with primary biliary cholangitis (PBC) and TH023, an oral anti-TNFα program targeting autoimmune diseases. An early-stage multispecific biologic platform utilizes proprietary EpiClick™ Technology to address multiple solid tumors.
Corporate Structure
Founded with a team of approximately 11–50 employees, THARIMMUNE leverages a license agreement with OmniAb, Inc. to access antibody discovery technology. Leadership includes:
- Sireesh Appajosyula, Chief Executive Officer (appointed June 2025), formerly SVP of Corporate Development at 9 Meters Biopharma
- Thomas Hess, Chief Financial Officer, with prior CFO roles at Genomind and Adolor Corporation
- Dr. Jay Rosenblatt, Head of CMC, who developed processes leading to commercial approval of Stelara® and Simponi®
Recent Developments and News
- On August 20, 2025, THAR’s share price closed at $1.84, a 57.26% increase, with 17,266,745 shares traded.
- On August 14, 2025, the Company filed its Form 10-Q for the quarter ended June 30, 2025, providing details on revenue, R&D and G&A expenses, net loss, and cash flow metrics.
- On August 7, 2025, THARIMMUNE submitted an 8-K (Items 5.02, 8.01, 9.01) addressing corporate disclosures and governance updates.
- The U.S. Food and Drug Administration confirmed in May 2025 that no additional clinical trials are required prior to NDA submission for TH104 under the 505(b)(2) pathway.
- TH104 is Phase 2 ready in both the U.S. and EU, with FDA and EMA feedback received. TH023 is progressing toward Phase 1 clinical planning.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Stock Price (8/20/2025) | $1.84 (▲57.26%) |
| Volume (8/20/2025) | 17,266,745 |
| Market Cap (intraday) | $7.6 M |
| Total Cash (MRQ) | $2.24 M |
| Total Debt/Equity (MRQ) | 90.99% |
| Net Loss (TTM) | $12.01 M |
The FDA’s confirmation on the 505(b)(2) pathway facilitates the potential submission of a New Drug Application (NDA) for TH104 in 2026 without the necessity of additional clinical trials. This regulatory clarity, along with a diversified pipeline covering rare liver disease and oncology, positions THARIMMUNE to navigate development risks and funding requirements.
Market Position and Industry Context
Operating within the NASDAQ small-cap biotechnology sector, THARIMMUNE targets niches that may be underserved by larger pharmaceutical companies. Its focus on a proprietary transmucosal buccal film for TH104 and oral biologic delivery for TH023 addresses specific medical needs. Partnerships—such as the OmniAb license—and internal platforms (EpiClick™) support its multi-specific antibody approach against targets like PD-1, HER2, and HER3.
TL;DR
As of August 20, 2025, THARIMMUNE’s stock increased 57.26% to $1.84 on significant trading volume. On August 14, the Company filed its Q2 10-Q, and on August 7 submitted an 8-K covering governance matters. In May 2025, the FDA confirmed a 505(b)(2) NDA pathway for TH104 without additional trials, facilitating a 2026 NDA submission. TH104 is Phase 2 ready in the U.S. and EU, while TH023 is progressing toward Phase 1 planning.